No profile data available.
MiNK Therapeutics, Inc. (INKT) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in New York, United States, with about 15 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$12.49 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $54.70 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
MiNK Therapeutics reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$54.70 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include XBiotech Inc. (XBIT), Metagenomi, Inc. (MGX), Eloxx Pharmaceuticals, Inc. (ELOX), Impact BioMedical Inc. (IBO).